tert-butyl 4-((6-(trifluoromethyl)pyridin-3-yl)oxy)piperidine-1-carboxylate | 1353754-93-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: tert-butyl 4-((6-(trifluoromethyl)pyridin-3-yl)oxy)piperidine-1-carboxylate
• 英文别名: Tert-butyl 4-[6-(trifluoromethyl)pyridin-3-yl]oxypiperidine-1-carboxylate
• CAS: 1353754-93-4
• 化学式: C₁₆H₂₁F₃N₂O₃
• 分子量: 346.35
• InChiKey: WSZHOJOPBZWACZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  24
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  51.7
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  tert-butyl 4-((6-(trifluoromethyl)pyridin-3-yl)oxy)piperidine-1-carboxylate 在 三氟乙酸 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 4.0h， 生成 (6S)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazin-6-yl 4-{[6-(trifluoromethyl)pyridin-3-yl]oxy}piperidine-1-carboxylate
  参考文献：
  名称：

  Structure–Activity Relationships for Amide-, Carbamate-, And Urea-Linked Analogues of the Tuberculosis Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)

  摘要：

  Analogues of clinical tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824), in which the OCH2 linkage was replaced with amide, carbamate, and urea functionality, were investigated as an alternative approach to address oxidative metabolism, reduce lipophilicity, and improve aqueous solubility. Several soluble monoaryl examples displayed moderately improved (similar to 2- to 4-fold) potencies against replicating Mycobacterium tuberculosis but were generally inferior inhibitors under anaerobic (nonreplicating) conditions. More lipophilic biaryl derivatives mostly displayed similar or reduced potencies to these in contrast to the parent biaryl series. The leading biaryl carbamate demonstrated exceptional metabolic stability and a 5-fold better efficacy than the parent drug in a mouse model of acute M. tuberculosis infection but was poorly soluble. Bioisosteric replacement of this biaryl moiety by arylpiperazine resulted in a soluble, orally bioavailable carbamate analogue providing identical activity in the acute model, comparable efficacy to OPC-67683 in a chronic infection model, favorable pharmacokinetic profiles across several species, and enhanced safety.

  DOI：

  10.1021/jm2012276
• 作为产物：
  描述：

  6-(三氟甲基)吡啶-3-醇 、 N-Boc-4-羟基哌啶 在 偶氮二甲酸二叔丁酯 、 三苯基膦 作用下， 以 四氢呋喃 为溶剂， 反应 18.0h， 以78%的产率得到tert-butyl 4-((6-(trifluoromethyl)pyridin-3-yl)oxy)piperidine-1-carboxylate
  参考文献：
  名称：

  [EN] OGA INHIBITOR COMPOUNDS
  [FR] COMPOSÉS INHIBITEURS D'OGA

  摘要：

  本发明涉及具有式(I)所示结构的O-GIcNAc水解酶（OGA）抑制剂。该发明还涉及包含这种化合物的药物组合物、制备这种化合物和组合物的方法，以及利用这种化合物和组合物预防和治疗抑制OGA有益的疾病，如tau病变，特别是阿尔茨海默病或进行性上核性麻痹；以及伴有tau病理的神经退行性疾病，特别是由C90RF72突变引起的肌萎缩侧索硬化或额颞叶痴呆症。其中RB是从（b-1）到（b-6）组成的芳香杂双环基团。

  公开号：

  WO2019243530A1

文献信息

• Design, synthesis, and pharmacological evaluation of a novel series of hormone sensitive lipase inhibitor
  作者：Tomoko Ogiyama、Mitsuhiro Yamaguchi、Nobuya Kurikawa、Shoko Honzumi、Koji Terayama、Nobumi Nagaoka、Yuka Yamamoto、Takako Kimura、Daisuke Sugiyama、Shin-ichi Inoue

  DOI：10.1016/j.bmc.2017.07.028

  日期：2017.9

  result of re-optimization of lead compound 2, we identified novel compound 25a exhibiting potent inhibitory activity against HSL enzyme and cell with high selectivity for cholinesterases (AChE and BuChE). Reflecting its potent in vitro activity, compound 25a exhibited antilipolytic effect in rats at 1 mg/kg p.o., which indicated that this novel compound is the most potent orally active HSL inhibitor.

  抑制HSL是治疗血脂异常的一种有前途的方法。作为重新优化铅化合物2的结果，我们确定了对HSL酶和对胆碱酯酶（AChE和BuChE）具有高选择性的细胞表现出有效抑制活性的新型化合物25a。化合物25a以1 mg / kg po的剂量在大鼠中表现出抗脂解作用，这表明该化合物是最有效的口服活性HSL抑制剂，反映了其强大的体外活性。此外，化合物25a没有显示出生物活化责任。
• [EN] SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF<br/>[FR] MODULATEURS À PETITES MOLÉCULES DE L'ACTIVITÉ GLUCOCÉRÉBROSIDASE ET LEURS UTILISATIONS
  申请人：VANQUA BIO INC

  公开号：WO2022232383A1

  公开（公告）日：2022-11-03

  Provided herein are compounds that modulate glucocerebrosidase (GCase), an enzyme whose activity is associated with neurological diseases and disorders (e.g., Gaucher's disease, Parkinson's disease). Also provided are pharmaceutical compositions and kits comprising the compounds, and methods of treating GCase-related diseases and disorders (e.g., Gaucher's disease, Parkinson's disease) with the compounds in a subject, by administering the compounds and/or compositions described herein.

  本文提供了一些化合物，这些化合物可以调节葡萄糖鞘脂酶(GCase)的活性，该酶的活性与神经系统疾病和障碍（例如高谷氏病，帕金森病）有关。此外，本文还提供了包含这些化合物的药物组合物和工具箱，并提供了使用本文所述的化合物和/或组合物治疗受试者的GCase相关疾病和障碍（例如高谷氏病，帕金森病）的方法，通过给受试者施用这些化合物和/或组合物。
• OGA INHIBITOR COMPOUNDS
  申请人：Janssen Pharmaceutica NV

  公开号：US20210122763A1

  公开（公告）日：2021-04-29

  The present invention relates to O-GlcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C9ORF72 mutations.